| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15d42f684941d5b0617ca7764ebdff07 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-06013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-01076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-01045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-0102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y301-04012 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-465
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46 |
| filingDate |
2007-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e0864836c606ab97572cda139e9cca0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df7a72b8af3448371b0d29dcd13681c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a47204dbb200ae777ab50d03c20038ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a8e35e796183c230130daba2535bac2 |
| publicationDate |
2019-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2716206-T3 |
| titleOfInvention |
Intraventricular enzyme distribution for lysosomal deposition diseases |
| abstract |
An acid sphingomyelinase for use in the prevention or treatment of Niemann-Pick A or B disease in a patient, wherein said prevention or treatment comprises intraventricular administration of acid sphingomyelinase to the patient's brain, in which the administration of A single dose of acid sphingomyelinase consumes more than five hours. |
| priorityDate |
2006-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |